Healio
Healio

American Academy of Ophthalmology Meeting
ByMarco A. Zarbin, MD, PhD
ByDavid W. Mullin
Fact checked byEamon N. Dreisbach

Read more

November 08, 2023
5 min watch
Save

VIDEO: Analysis finds similar BCVA, superior CST for faricimab vs. aflibercept in DME

ByMarco A. Zarbin, MD, PhD
ByDavid W. Mullin
Fact checked byEamon N. Dreisbach
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Marco A. Zarbin, MD, PhD, FACS, discusses a post hoc analysis of faricimab vs. aflibercept in patients with DME and visual acuity of 20/50 or worse.

The post hoc analysis of the YOSEMITE and RHINE studies found similar visual acuity results between patients treated with faricimab or aflibercept but superior central subfield thickness in patients treated with faricimab at years 1 and 2, according to Zarbin.

Sources/Disclosures

Collapse
Source:

Zarbin M., et al. Clinical outcomes of patients with DME presenting with 20/50 VA treated with faricimab and aflibercept. Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco.

Disclosures: Zarbin reports consulting for Genentech/Roche.

Read more about

visual acuity
faricimab
aflibercept
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

 

Related Content